vs
Apellis Pharmaceuticals, Inc.（APLS）与EVERTEC, Inc.（EVTC）财务数据对比。点击上方公司名可切换其他公司
EVERTEC, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$244.8M vs $199.9M），EVERTEC, Inc.净利率更高（15.1% vs -29.5%，领先44.6%），EVERTEC, Inc.同比增速更快（13.1% vs -5.9%），EVERTEC, Inc.自由现金流更多（$63.7M vs $-14.3M），过去两年EVERTEC, Inc.的营收复合增速更高（9.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
EVERTEC Inc.是总部位于波多黎各的领先全品类支付技术与交易处理服务商，主要面向拉丁美洲及加勒比地区的金融机构、零售商户和政府客户，提供商户收单、电子资金转账、数字支付解决方案及业务流程外包服务。
APLS vs EVTC — 直观对比
营收规模更大
EVTC
是对方的1.2倍
$199.9M
营收增速更快
EVTC
高出19.1%
-5.9%
净利率更高
EVTC
高出44.6%
-29.5%
自由现金流更多
EVTC
多$78.0M
$-14.3M
两年增速更快
EVTC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $244.8M |
| 净利润 | $-59.0M | $37.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 17.6% |
| 净利率 | -29.5% | 15.1% |
| 营收同比 | -5.9% | 13.1% |
| 净利润同比 | -62.2% | -8.9% |
| 每股收益（稀释后） | $-0.40 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEVTC
| Q4 25 | $199.9M | $244.8M | ||
| Q3 25 | $458.6M | $228.6M | ||
| Q2 25 | $178.5M | $229.6M | ||
| Q1 25 | $166.8M | $228.8M | ||
| Q4 24 | $212.5M | $216.4M | ||
| Q3 24 | $196.8M | $211.8M | ||
| Q2 24 | $199.7M | $212.0M | ||
| Q1 24 | $172.3M | $205.3M |
净利润APLSEVTC
| Q4 25 | $-59.0M | $37.0M | ||
| Q3 25 | $215.7M | $32.9M | ||
| Q2 25 | $-42.2M | $40.5M | ||
| Q1 25 | $-92.2M | $32.7M | ||
| Q4 24 | $-36.4M | $40.7M | ||
| Q3 24 | $-57.4M | $24.7M | ||
| Q2 24 | $-37.7M | $31.9M | ||
| Q1 24 | $-66.4M | $16.0M |
营业利润率APLSEVTC
| Q4 25 | -25.6% | 17.6% | ||
| Q3 25 | 48.7% | 16.5% | ||
| Q2 25 | -18.6% | 24.4% | ||
| Q1 25 | -50.0% | 21.6% | ||
| Q4 24 | -12.3% | 22.2% | ||
| Q3 24 | -24.0% | 19.6% | ||
| Q2 24 | -14.7% | 20.5% | ||
| Q1 24 | -36.0% | 16.0% |
净利率APLSEVTC
| Q4 25 | -29.5% | 15.1% | ||
| Q3 25 | 47.0% | 14.4% | ||
| Q2 25 | -23.6% | 17.6% | ||
| Q1 25 | -55.3% | 14.3% | ||
| Q4 24 | -17.1% | 18.8% | ||
| Q3 24 | -29.2% | 11.7% | ||
| Q2 24 | -18.9% | 15.0% | ||
| Q1 24 | -38.5% | 7.8% |
每股收益（稀释后）APLSEVTC
| Q4 25 | $-0.40 | $0.57 | ||
| Q3 25 | $1.67 | $0.51 | ||
| Q2 25 | $-0.33 | $0.62 | ||
| Q1 25 | $-0.74 | $0.50 | ||
| Q4 24 | $-0.30 | $0.62 | ||
| Q3 24 | $-0.46 | $0.38 | ||
| Q2 24 | $-0.30 | $0.49 | ||
| Q1 24 | $-0.54 | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $306.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $621.6M |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEVTC
| Q4 25 | $466.2M | $306.0M | ||
| Q3 25 | $479.2M | $474.7M | ||
| Q2 25 | $370.0M | $290.6M | ||
| Q1 25 | $358.4M | $265.9M | ||
| Q4 24 | $411.3M | $273.6M | ||
| Q3 24 | $396.9M | $275.4M | ||
| Q2 24 | $360.1M | $257.7M | ||
| Q1 24 | $325.9M | $293.7M |
总债务APLSEVTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSEVTC
| Q4 25 | $370.1M | $621.6M | ||
| Q3 25 | $401.2M | $663.8M | ||
| Q2 25 | $156.3M | $612.3M | ||
| Q1 25 | $164.2M | $542.1M | ||
| Q4 24 | $228.5M | $472.5M | ||
| Q3 24 | $237.1M | $502.6M | ||
| Q2 24 | $264.3M | $483.4M | ||
| Q1 24 | $266.7M | $507.3M |
总资产APLSEVTC
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $1.9B | ||
| Q3 24 | $901.9M | $1.9B | ||
| Q2 24 | $904.5M | $1.9B | ||
| Q1 24 | $831.9M | $2.0B |
负债/权益比APLSEVTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $70.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $63.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 26.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.89× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $203.7M |
8季度趋势，按日历期对齐
经营现金流APLSEVTC
| Q4 25 | $-14.2M | $70.0M | ||
| Q3 25 | $108.5M | $70.9M | ||
| Q2 25 | $4.4M | $48.5M | ||
| Q1 25 | $-53.4M | $37.6M | ||
| Q4 24 | $19.4M | $75.2M | ||
| Q3 24 | $34.1M | $53.6M | ||
| Q2 24 | $-8.3M | $90.6M | ||
| Q1 24 | $-133.0M | $40.7M |
自由现金流APLSEVTC
| Q4 25 | $-14.3M | $63.7M | ||
| Q3 25 | $108.3M | $65.3M | ||
| Q2 25 | $4.4M | $43.5M | ||
| Q1 25 | $-53.4M | $31.2M | ||
| Q4 24 | $19.3M | $70.8M | ||
| Q3 24 | — | $49.7M | ||
| Q2 24 | $-8.4M | $78.8M | ||
| Q1 24 | $-133.3M | $35.3M |
自由现金流率APLSEVTC
| Q4 25 | -7.1% | 26.0% | ||
| Q3 25 | 23.6% | 28.5% | ||
| Q2 25 | 2.5% | 18.9% | ||
| Q1 25 | -32.0% | 13.7% | ||
| Q4 24 | 9.1% | 32.7% | ||
| Q3 24 | — | 23.5% | ||
| Q2 24 | -4.2% | 37.2% | ||
| Q1 24 | -77.3% | 17.2% |
资本支出强度APLSEVTC
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 2.0% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 5.6% | ||
| Q1 24 | 0.2% | 2.6% |
现金转化率APLSEVTC
| Q4 25 | — | 1.89× | ||
| Q3 25 | 0.50× | 2.16× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 1.85× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 2.84× | ||
| Q1 24 | — | 2.55× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVTC
| Latin America Payments And Solutions | $101.5M | 41% |
| Business Solutions | $58.3M | 24% |
| Merchant Acquiring Net | $48.2M | 20% |
| Payment Services Puerto Rico Caribbean | $36.8M | 15% |
| Transferred At Point In Time | $4.0M | 2% |
